Research progress of biologics for the treatment of immune checkpoint inhibitor-induced colitis
10.3760/cma.j.cn101480-20221213-00204
- VernacularTitle:生物制剂治疗免疫检查点抑制剂相关性结肠炎的研究进展
- Author:
Ling LIU
1
;
Wenxiao DONG
;
Bangmao WANG
;
Hailong CAO
Author Information
1. 天津医科大学总医院消化科，天津 300070
- Publication Type:Journal Article
- Keywords:
Immune checkpoint inhibitors;
Colitis;
Biologics
- From:
Chinese Journal of Inflammatory Bowel Diseases
2023;07(4):355-359
- CountryChina
- Language:Chinese
-
Abstract:
Recently immune checkpoint inhibitors (ICIs) have been widely used in the treatment of tumors. ICIs-induced colitis is the most common cause of immunotherapy interruption, permanent discontinuation and treatment-related death. Corticosteroids are the first-line therapy. If there is no response or intolerance to corticosteroid, biologics can be selected for treatment. Although there are similarities between ICIs-induced colitis and inflammatory bowel disease, it is considered to be a different form of colitis with a more acute onset, which can rapidly deteriorate into ileus, megacolon, peritonitis, intestinal perforation, or even death. Timely recognition and management are crucial. This review summarizes the efficacy and safety of biological agents in the treatment of ICIs-induced colitis and their influence on the anti-tumor effects of ICIs.
